1. PUBLICATIONS
Ho TH,Kapur P,Joseph RW, Serie DJ,Eckel-Passow JE,Parasramka M,Cheville JC, Wu KJ, Frenkel E, Rakheja
D, Stefanius K,Brugarolas J, Parker AS. Urol Oncol.2014 Nov 24. Loss of PBRM1 and BAP1 expression is less
common in non-clear cell renal cell carcinoma than in clear cell renal cell carcinoma. doi:
10.1016/j.urolonc.2014.10.014. http://www.ncbi.nlm.nih.gov/pubmed/25465300
Wang SS, Gu YF, Wolff N, Stefanius K,Christie A, Dey A, Hammer RE, Xie XJ, Rakheja D, Pedrosa I, Carroll T,
McKay RM, Kapur P, Brugarolas J. Proc Natl Acad Sci U S A. 2014 Nov 18;111(46):16538-43. Bap1 is essential for
kidney function and cooperates with Vhl in renal tumorigenesis. doi: 10.1073/pnas.1414789111.
http://www.ncbi.nlm.nih.gov/pubmed/25359211
Stefanius K,Ylitalo L, Kuivila R, Kantola T, Sirniö P,Karttunen TJ & Makinen MJ (2011) Frequent mutations of
KRAS in addition to BRAF in colorectal serrated adenocarcinoma. Histopathology.2011 Apr;58(5):679-92. doi:
10.1111/j.1365-2559.2011.03821.x. http://www.ncbi.nlm.nih.gov/pubmed/21457162
Stefanius K,Kantola T, Tuomisto A, Vahteristo P, Karttunen TJ, Aaltonen LA, Mäkinen MJ & Karhu A. (2011)
Downregulation of the hedgehog receptor PTCH1 in colorectal serrated adenocarcinomas is not caused by PTCH1
mutations. Virchows Arch. 2011 Feb;458(2):213-9. http://www.ncbi.nlm.nih.gov/pubmed/21234763
Heliövaara E, Raitila A, Launonen V, Paetau A,Arola J, Lehtonen H, Sane T, Weil RJ, Vierimaa O, Salmela P,
Tuppurainen K, Mäkinen M, Aaltonen LA, Karhu A. (2009) The expression of AIP-related molecules in elucidation
of cellular pathways in pituitary adenomas. Am J Pathol. 2009 Dec;175(6):2501-7.
http://www.ncbi.nlm.nih.gov/pubmed/19850893
Raitila A, Georgitsi M, Bonora E, Vargiolu M, Tuppurainen K,Mäkinen MJ, Vierimaa O,Salmela PI, Launonen V,
Vahteristo P,Aaltonen LA, Romeo G, Karhu A. (2009) Aryl hydrocarbon receptor interacting protein mutations seem
not to associate with familial non-medullary thyroid cancer. J Endocrinol Invest.2009 May;32(5):426-9.
http://www.ncbi.nlm.nih.gov/pubmed/19794292
Georgitsi M, De Menis E, Cannavò S, Mäkinen MJ, Tuppurainen K, Pauletto P,Curtò L, Weil RJ, Paschke R,
Zielinski G, Wasik A, Lubinski J, Vahteristo P,Karhu A, Aaltonen LA. (2008) Aryl hydrocarbon receptor interacting
protein (AIP) gene mutation analysis in children and adolescents with sporadic pituitary adenomas. Clin Endocrinol
69(4):621-7. http://www.ncbi.nlm.nih.gov/pubmed/18410548
Georgitsi M, Raitila A, Karhu A, van der Luijt RB, Aalfs CM, Sane T , Vierimaa O, Mäkinen MJ, Tuppurainen K,
Paschke R,Gimm O, Koch CA, Gündogdu S, Lucassen A,Kumar VKA,Tischkowitz M, Izatt L, Aylwin S, Bano G,
Hodgson S, De Menis E, Launonen V, Vahteristo P,Aaltonen LA (2007). Germline CDKN1B/p27Kip1 mutation in
multiple endocrine neoplasia. J Clin Endocrinol Metab 92(8):3321-5.
http://www.ncbi.nlm.nih.gov/pubmed/17519308
Georgitsi M, Raitila A, Karhu A, Tuppurainen K,Mäkinen M, Vierimaa O, Paschke R,Saeger W,van der Luijt R,
Sane T, Robledo M, De Menis E, Weil R, Lubinski J, Launonen V, Vahteristo P,Aaltonen LA (2007). Molecular
diagnosis of pituitary adenoma predisposition (PAP) caused by AIP mutations. PNAS 104(10): 4101-5.
http://www.ncbi.nlm.nih.gov/pubmed/17360484
Raitila A, Georgitsi M, Karhu A, Tuppurainen K,Mäkinen MJ, Birkenkamp-Demtröder K, Salmenkivi K, Orntoft
TF, Arola J, Launonen V, Vahteristo P & Aaltonen LA (2007). No evidence of somatic AIP mutations in sporadic
endocrine neoplasia. Endocr Relat. Cancer 14(3):901-6. http://www.ncbi.nlm.nih.gov/pubmed/17914118
Laiho P,Kokko A, Vanharanta S, Salovaara R, Sammalkorpi H, Järvinen H, Mecklin J-P,Karttunen TJ,
Tuppurainen K, Davalos V, Schwartz S Jr., Arango D, Mäkinen MJ, Aaltonen LA (2007). Serrated Carcinomas
Form a Subclass of Colorectal Cancer with Distinct Molecular Basis. Oncogene 26(2):312-20.
http://www.ncbi.nlm.nih.gov/pubmed/16819509
Vierimaa O, Georgitsi M, Lehtonen R, Vahteristo P,Kokko A, Raitila A, Tuppurainen K, Ebeling TM, Salmela PI,
Paschke R,Gundogdu S, De Menis E, Makinen MJ, Launonen V, Karhu A, Aaltonen LA (2006). Pituitary adenoma
predisposition caused by germline mutations in the AIP gene. Science 26;312(5777):1228-30.
http://www.ncbi.nlm.nih.gov/pubmed/16728643

2. Klintrup K, Mäkinen JM, Kauppila S, Väre PO,Melkko J, Tuominen H, Tuppurainen K,Mäkelä J, Karttunen TJ,
Mäkinen MJ (2005). Inflammation and Prognosis in Colorectal Cancer. Eur J Cancer 41(17):2645-54.
http://www.ncbi.nlm.nih.gov/pubmed/16239109
Hörkkö TT, Tuppurainen K,Harrison SM, Jernvall P, Karttunen TJ, Mäkinen MJ. (2005) Thyroid hormone receptor
1 in normal colon and colorectal cancer – association with differentiation, polypoid growth type and K-ras mutations.
Int J Cancer 118;(7):1653-9. http://www.ncbi.nlm.nih.gov/pubmed/16231318
Tuppurainen K, Mäkinen JM, Junttila O, Liakka A, Kyllönen AP,Tuominen H, Karttunen TJ, Mäkinen MJ. (2005)
Morphology and microsatellite instability in serrated and sporadic non-serrated colorectal cancer. J Pathol
207(3):285-94. http://www.ncbi.nlm.nih.gov/pubmed/16177963
CONFERENCES ANDPRESENTATIONS
Stefanius K, Orth K. ER Chaperone BiP –A unique role in Cancer Cells. Innovations in Cancer Prevention and
Research Conference,CPRIT 2015,Austin, USA, November 2015. Abstract,poster presentation.
Tuppurainen K, Karhu A, Kantola T, Vahteristo P, Karttunen TJ, Aaltonen LA, Mäkinen MJ. Dowregulation of the
hedgehog receptor Patched-1 is not caused by inactivating mutations of PTCH1 in serrated cancer. ICR Centenary
conferense 2009, London, UK,June 2009. Abstract,poster presentation.
Pukkila L, Tuppurainen K,Karttunen TJ, Mäkinen MJ. The essential role of KRAS and BRAF mutations in serrated
adenocarcinomas. EACR 20 France, Lyon July 2008. Abstract,poster presentation.
Tuppurainen K, Pukkila L, Kuivila R, Karttunen TJ, Mäkinen MJ. Colorectal serrated adenocarcinoma: Mutations of
BRAF and KRAS and their association with DNA hypermethylation and MSI. Mechanisms and models of cancer –
meeting, USA,New York, Cold Spring Harbour, August 2008. Abstract,poster presentation.
Kantola T, Tuppurainen K, Horkko TT, Karttunen TJ, Eskelinen S, Mäkinen MJ. Thyroid hormone T3 modulates
protein synthesis and induces nuclear targeting of TR receptors in Caco-2 cells. NCRI Cancer conference,
Birminghamn, UK,September 30 – October 3 2007. Abstract,poster presentation.
Tuppurainen K, Kuivila R, Karttunen TJ, Mäkinen MJ. Frequent loss of TMEFF2/HPP1 and microsatellite
instability in colorectal serrated adenocarcinoma.EACR 19, Budapest, Hungary, July 2006. Abstract,poster
presentation.
Mäkinen MJ, Tuppurainen K, Harrison SM, Karttunen TJ. Features of colorectal cancers arising adjacent to sessile
serrated adenoma. Virchows Arch 280:159, 2005. Abstract,poster presentation.
Tuppurainen K, Junttila O, Karttunen TJ, Mäkinen MJ. Microsatellite instability and mismatch repair in serrated and
sporadic colorectal cancer. Faculty of Medicine Science Day, Oulu, Finland, February 22, 2005. Abstract,poster
presentation.
Mäkinen M, Tuppurainen K, Junttila O, Karttunen TJ. MSI-L and MSI-H in colorectal serrated adenocarcinomas.
19th
2003. Virchows Arch 443:389, 2003. Abstract,poster presentation. European Congress of Pathology, Ljublijana,
Slovenia, September 6-11,